Scarica l'app Stockscreener
19.43
2.32%
0.425
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.00
Aprire:
$19.01
Volume 24 ore:
151.40K
Relative Volume:
0.45
Capitalizzazione di mercato:
$1.07B
Reddito:
$29.71M
Utile/perdita netta:
$-69.15M
Rapporto P/E:
-37.87
EPS:
-0.513
Flusso di cassa netto:
$-52.28M
1 W Prestazione:
+4.52%
1M Prestazione:
+11.92%
6M Prestazione:
+52,158%
1 anno Prestazione:
+52,158%
Intervallo 1D:
$18.75
$19.92
Intervallo di 1 settimana:
$17.95
$20.24
Portata 52W:
$14.72
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Nome
Aktis Oncology Inc
Settore
Industria
Telefono
978-237-4380
Indirizzo
17 DRYDOCK AVENUE, BOSTON, NC
Compare AKTS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
19.44 | 1.07B | 29.71M | -69.15M | -52.28M | -0.513 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-09 | Iniziato | H.C. Wainwright | Buy |
| 2026-02-03 | Iniziato | BofA Securities | Buy |
| 2026-02-03 | Iniziato | JP Morgan | Overweight |
| 2026-02-03 | Iniziato | Leerink Partners | Outperform |
| 2026-02-03 | Iniziato | TD Cowen | Buy |
| 2024-01-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | Iniziato | B. Riley Securities | Buy |
| 2021-02-02 | Reiterato | Craig Hallum | Buy |
| 2021-01-15 | Reiterato | Craig Hallum | Buy |
| 2019-09-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | Reiterato | Craig Hallum | Buy |
| 2019-02-05 | Reiterato | Craig Hallum | Buy |
| 2019-02-05 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | Iniziato | Craig Hallum | Buy |
| 2018-11-30 | Iniziato | Lake Street | Buy |
| 2018-06-22 | Iniziato | Loop Capital | Buy |
| 2018-02-09 | Iniziato | Drexel Hamilton | Buy |
Mostra tutto
Aktis Oncology Inc Borsa (AKTS) Ultime notizie
William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
AKTS: AKY-2519 advances in Phase I-B trials for mCRPC and B7H3-expressing tumors, with key data ahead - TradingView
Top Cybin (HELP) Competitors 2026 - MarketBeat
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer - Investing.com
Aktis opens prostate cancer study as it broadens AKY-2519 testing - Stock Titan
Aktis Oncology Initiates Phase 1b Clinical Trial for - GlobeNewswire
UCB strikes up to $2.2B Candid deal, spotlighting Two River and Vida - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday - Sahm
William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating, Announces Target Price $32 - Moomoo
William Blair Initiates Aktis Oncology at Outperform - Moomoo
William Blair initiates coverage of Aktis Oncology (AKTS) with outperform recommendation - MSN
Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting (AKTS) - Seeking Alpha
Massachusetts biotech IPOs surge after years of drought - The Business Journals
Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump - Yahoo Finance
Aktis Oncology prices IPO at $18 per share - MSN
Economics Weekly: Capacity Growth—It’s Different This Time - William Blair
Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Intuitive Surgical (ISRG) - The Globe and Mail
Aktis Oncology to Present Clinical Data on AKY-2519 Targeting B7-H3 at 2026 ASCO Annual Meeting - Quiver Quantitative
Two ASCO posters give first look at how Aktis cancer drug moves in tumors - Stock Titan
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - ChartMill
Is Aktis (AKTS) stock forming a squeeze pattern (Buying Pressure) 2026-04-18Expert Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know - Yahoo Finance
Aktis Oncology appoints Glenn Gormley to board of directors By Investing.com - Investing.com India
Director at Aktis Oncology (NASDAQ: AKTS) awarded 37,866 stock options - Stock Titan
Aktis Oncology (AKTS) director Glenn Gormley files initial insider Form 3 - Stock Titan
Veteran pharma leader Glenn Gormley joins Aktis Oncology (AKTS) board as director - Stock Titan
Glenn Gormley Joins Aktis Oncology Board of Directors to Support Cancer Treatment Initiatives - geneonline.com
Aktis Oncology appoints Glenn Gormley to board of directors - Investing.com
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors - GlobeNewswire
Glenn Gormley Net Worth (2026) - GuruFocus
H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33 - Insider Monkey
5 Healthcare Stocks Insiders Are Buying - Insider Monkey
Biopharma IPOs Had Their Best Showing In More Than A Year In Q1 - Citeline News & Insights
AMPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aktis Oncology, Inc.: Fundamental Analysis and Financial Ratings | AKTS | US01021M1045 - marketscreener.com
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target - TipRanks
Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat
Aktis Oncology’s AKY-2519 gains IND approvals - BioWorld MedTech
H.C. Wainwright raises Akoustis Technologies price target on pipeline progress - Investing.com Canada
AKTS: Analyst Raises Price Target, Maintains 'Buy' Rating | AKTS Stock News - GuruFocus
FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial By Investing.com - Investing.com Australia
Aktis Oncology (NASDAQ: AKTS) secures IND clearances and multi-year cash runway - Stock Titan
AKTS: Strong cash position post-IPO and Eli Lilly deal supports clinical pipeline through 2029 - TradingView
Aktis Oncology (NASDAQ: AKTS) outlines miniprotein alpha radiopharma strategy - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment - marketscreener.com
FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial - Investing.com
Aktis Oncology Inc Azioni (AKTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aktis Oncology Inc Azioni (AKTS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| GADICKE ANSBERT | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| EcoR1 Capital, LLC | Director |
Jan 12 '26 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
4,348,658 |
| Vida Ventures II, LLC | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
| Kim Helen Susan | Director |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):